A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent
| Autor: | Rushab Choksi, Mohannad Bisharat, Stephanie Niman, Majdi Ashchi, Jessica Huston, Heather Hartmann, Rebecca F Goldfaden, Jennifer Hardy |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Statin Clinical pharmacology business.industry medicine.drug_class PCSK9 General Medicine Disease medicine.disease law.invention Coronary artery disease Pharmacotherapy Ezetimibe law Internal medicine medicine Humans Pharmacology (medical) Cardiology and Cardiovascular Medicine business Stroke Hypolipidemic Agents Lipoprotein(a) medicine.drug |
| Zdroj: | American Journal of Cardiovascular Drugs. 22:47-54 |
| ISSN: | 1179-187X 1175-3277 |
| DOI: | 10.1007/s40256-021-00499-1 |
| Popis: | Patients with genetically associated elevated lipoprotein(a) [Lp(a)] levels are at greater risk for coronary artery disease, heart attack, stroke, and peripheral arterial disease. To date, there are no US FDA-approved drug therapies that are designed to target Lp(a) with the goal of lowering the Lp(a) level in patients who have increased risk. The American College of Cardiology (ACC) has provided guidelines on how to use traditional lipid profiles to assess the risk of atherosclerotic cardiovascular disease (ASCVD); however, even with the emergence of statin add-on therapies such as ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, some populations with elevated Lp(a) biomarkers remain at an increased risk for cardiovascular (CV) disease. Residual CV risk has led researchers to inquire about how lowering Lp(a) can be used as a potential preventative therapy in reducing CV events. This review aims to present and discuss the current clinical and scientific evidence pertaining to pelacarsen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink